DDInter388 DDInter1376
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Citalopram {u} (Compound) resembles {v} (Compound) Escitalopram
Citalopram {u} (Compound) treats {v} (Disease) alcohol dependence
Citalopram {u} (Compound) binds {v} (Gene) HTR2C
Citalopram {u} (Compound) upregulates {v} (Gene) PLS1
Citalopram {u} (Compound) palliates {v} (Disease) panic disorder
Citalopram {u} (Compound) downregulates {v} (Gene) RNH1
Citalopram {u} (Compound) causes {v} (Side Effect) Allergy aggravated
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Citalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Citalopram (Compound) resembles Escitalopram (Compound)
Citalopram (Compound) treats alcohol dependence (Disease)
Citalopram (Compound) binds HTR2C (Gene)
Citalopram (Compound) upregulates PLS1 (Gene)
Citalopram (Compound) palliates panic disorder (Disease)
Citalopram (Compound) downregulates RNH1 (Gene)
Citalopram (Compound) causes Allergy aggravated (Side Effect)
Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin